MilliporeSigma to invest $286M to meet swelling biosafety testing demands

Nov. 17, 2022

MilliporeSigma, the US. And Canada Life Science business of Merck KGaA, announced this week that it would be investing more than $286 million in expanding its biosafety testing capacities at its Rockville, Maryland site.

According to the company, global demand for these services is growing at a double-digit rate — and this investment will help MilliporeSigma meet these needs. It also accounts for the largest investment in contract testing in Merck KGaA history. The expansion to the Maryland site will include a new state-of-the-art, 250,000-square-foot facility that will house biosafety testing, analytical development, viral clearance suites, and cell bank manufacturing services. 

Other pharma companies that recently announced investments to support the development of their biologics portfolio include BMS, which earlier this month opened the doors to its new $1 billion biologics site in Dublin.